Quel est le prix pour Aardvark Therapeutics, Inc. Common Stock (AARD)

Le prix pour Aardvark Therapeutics, Inc. Common Stock (AARD) est $7.22

Quelle est la capitalisation boursière pour Aardvark Therapeutics, Inc. Common Stock (AARD)

La capitalisation boursière pour Aardvark Therapeutics, Inc. Common Stock (AARD) est $158.03M

Aardvark Therapeutics, Inc. Common Stock (AARD) Rendement du Dividende

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Année	Rendement du dividende	Changez
Pas assez de données pour les dates fournies.

Année

Rendement du dividende

Changez

Pas assez de données pour les dates fournies.

Entreprise	Rendement du dividende	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Moderna, Inc. MRNA.US	0.00%	US
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH

Entreprise

Rendement du dividende

Pays